Monday, July 08, 2024 5:20:07 PM
Before EWTX there was MYOK in HCM ...bt out at $225 a share .
EWTX hired some MYOK folks after this buyout
https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash/default.aspx
Kiwi
EWTX hired some MYOK folks after this buyout
https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash/default.aspx
Kiwi
Recent EWTX News
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:49:16 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/23/2026 08:10:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:07:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:06:20 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 04/01/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/27/2026 08:41:21 PM
- Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up • PR Newswire (US) • 03/10/2026 11:00:00 AM
- Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 • PR Newswire (US) • 03/04/2026 01:00:00 PM
- Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference • PR Newswire (US) • 03/03/2026 01:00:00 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 03/02/2026 02:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 01:05:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:00:52 PM
- Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs • PR Newswire (US) • 02/26/2026 01:00:00 PM
- Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 • PR Newswire (US) • 02/05/2026 01:00:00 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 02/02/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 06:34:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/21/2026 09:05:10 PM
- Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 • PR Newswire (US) • 01/13/2026 01:00:00 PM
- Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 • PR Newswire (US) • 01/06/2026 01:00:00 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 01/05/2026 01:00:00 PM
- Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy • PR Newswire (US) • 12/24/2025 01:00:00 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 12/02/2025 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/25/2025 12:06:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 10:07:45 PM
